Congrats to Dr Reed O’Connor and Dr chambers @LAURAJMOULTON on getting the FWC Harold and Barbara Rosenbaum family award @GYNCancer to study probiotic and dietary fiber to potentiate immunotherapy in cervical cancer @osugynonc @OSUCCC_James

So honored to receive the Larry J. Copeland, MD Endowed Professorship in Gynecologic Oncology @osugynonc @OSUCCC_James

Platinum sensitivity does not apply in endometrial cancer. Platinum-free interval (PFI) is associated with response to next therapy but is NOT better for platinum versus no platinum treatment. @gynoncjnls . Https://www.sciencedirect.co…

Drs. Colombo and Ray-Coquard share their thoughts on frontline PARP inhibitor maintenance for ovarian cancer and differences in overall survival and bevacizumab use . Is it study population, the drug, the combination, duration of treatment? #ESMO2024 @myESMO @SGO_org

⁦@BPothuri⁩ and Dr Tom Herzog comment on long term overall survival with niraparib maintenance in the ovarian cancer PRIMA trial and pembro added to adjuvant chemotherapy in endometrial cancer #esmo2024 ⁦@myESMO⁩ ⁦@SGO_org⁩ #esmo24

Dr Antonio Gonzalez summarizes his his distillation of the PICOLLO results presented by @AngelesSecord and Rina-S presented by Dr Elizabeth Lee on FRa targeting ADCs in platinum sensitive and resistant #ovarian cancer #ESMO24 @myESMO @SGO_org #esmo2024

@DrKatyMoore puts it all so well together and stresses the importance of predictive biomarkers to inform us which ADC to use for each individual patient and how to sequence them @SGO_org @myESMO #ESMO2024 #ESMO24

We have not been able to improve outcomes of PARP inhibitor maintenance in the second line. ICON9 shows no benefit of maintenance olaparib and cediranib over olaparib alone in platinum sensitive recurrent ovarian cancer and increased toxicity @myESMO @SGO_org #ESMO2024 #ESMO24

Again no benefit of immunotherapy in ovarian cancer . the addition of nivolumab to rucaparib as maintenance therapy for front line ovarian cancer did not results in better survival and increased toxicity. @myESMO @SGO_org #ESMO24

no OS benefit with niraparib first line maintenance therapy, but survival almost 70 months in HRD! I’m so relieved: no detrimental effect on OS and significant PFS benefit. 3x higher post progression PARPi use may have contributed to lack of OS benefit. @myESMO @SGO_org #ESMO24

“The most exciting negative study” ! While there was no benefit of pembro added to adjuvant chemotherapy in endometrial cancer, in dMMR pembro decreased the risk of recurrence or death but 70% (HR 0.3) ⁦@myESMO⁩ ⁦@SGO_org⁩ #esmo2024

avelumab + MTX was suggested as the new standard regimen for low risk GTD. Exciting >95% durable cure rate in stage 1-3, WHO score 1-6. @myESMO @SGO_org #esmo2024

Starting the day off #ESMO2024 with excellent education on how technology can help clinical care . Whole genome sequencing has the ability to pick up additional mutations and can inform new and additional therapeutic options @myESMO @SGO_org